PMID- 37692782
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230913
IS  - 2296-858X (Print)
IS  - 2296-858X (Electronic)
IS  - 2296-858X (Linking)
VI  - 10
DP  - 2023
TI  - Obesity is associated with pain and impaired mobility despite therapy in systemic 
      lupus erythematosus.
PG  - 1247354
LID - 10.3389/fmed.2023.1247354 [doi]
LID - 1247354
AB  - OBJECTIVE: To investigate whether abnormal BMI is associated with health-related 
      quality of life (HRQoL) impairments, defined as patient-reported problems within 
      the different dimensions of the three-level EQ-5D (EQ-5D-3L), before and after 
      treatment for active systemic lupus erythematosus (SLE). PATIENTS AND METHODS: We 
      conducted a post-hoc analysis of data from two phase III clinical trials of 
      belimumab in SLE, i.e., BLISS-52 (n = 865) and BLISS-76 (n = 819). Underweight 
      was defined as BMI <18.5 kg/m(2), normal weight as BMI >/=18.5 but <25 kg/m(2), 
      pre-obesity as BMI >/=25 but <30 kg/m(2), and obesity as BMI >/=30 kg/m(2). We 
      investigated associations between BMI groups and problems (level 2 or 3) within 
      each one of the five EQ-5D dimensions before treatment initiation and at week 52, 
      using logistic regression analysis adjusting for age, ethnicity, disease 
      activity, and glucocorticoid dose, and for the post-treatment analysis also for 
      belimumab treatment and baseline EQ-5D-3L responses. RESULTS: Of 1,684 patients 
      included, 73 (4%) were classified as underweight, 850 (50%) as normal weight, 438 
      (26%) as pre-obese, and 323 (19%) as obese. At baseline, obesity was associated 
      with mild to severe problems in all EQ-5D dimensions (p < 0.05 for all), yielding 
      the strongest association with problems in mobility (adjusted odds ratio, aOR: 
      2.1; 95% confidence interval, CI: 1.6-2.8; p < 0.001). Pre-obesity was also 
      associated with problems in mobility (aOR: 1.4; 95% CI: 1.1-1.8; p = 0.005). 
      Post-intervention, obesity was associated with problems in mobility and 
      pain/discomfort, and pre-obesity with problems in mobility and self-care 
      (p < 0.05 for all). CONCLUSION: Our study adds to the evidence that high BMI 
      negatively affects SLE patients' HRQoL, with obesity being associated with pain 
      and impaired mobility despite therapy.
CI  - Copyright (c) 2023 Borg, Lindblom, Gomez, Soltani, Enman, Heintz, Regardt, Grannas, 
      Emamikia and Parodis.
FAU - Borg, Alexander
AU  - Borg A
AD  - Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet and 
      Karolinska University Hospital, Stockholm, Sweden.
FAU - Lindblom, Julius
AU  - Lindblom J
AD  - Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet and 
      Karolinska University Hospital, Stockholm, Sweden.
FAU - Gomez, Alvaro
AU  - Gomez A
AD  - Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet and 
      Karolinska University Hospital, Stockholm, Sweden.
FAU - Soltani, Ameneh
AU  - Soltani A
AD  - Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet and 
      Karolinska University Hospital, Stockholm, Sweden.
FAU - Enman, Yvonne
AU  - Enman Y
AD  - Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet and 
      Karolinska University Hospital, Stockholm, Sweden.
FAU - Heintz, Emelie
AU  - Heintz E
AD  - Department of Learning, Informatics, Management and Ethics (LIME), Karolinska 
      Institutet, Stockholm, Sweden.
FAU - Regardt, Malin
AU  - Regardt M
AD  - Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, 
      Stockholm, Sweden.
AD  - Occupational Therapy and Physiotherapy, Karolinska University Hospital, 
      Stockholm, Sweden.
FAU - Grannas, David
AU  - Grannas D
AD  - Division of Biostatistics, Institute of Environmental Medicine, Karolinska 
      Institutet, Stockholm, Sweden.
FAU - Emamikia, Sharzad
AU  - Emamikia S
AD  - Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet and 
      Karolinska University Hospital, Stockholm, Sweden.
FAU - Parodis, Ioannis
AU  - Parodis I
AD  - Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet and 
      Karolinska University Hospital, Stockholm, Sweden.
AD  - Department of Rheumatology, Faculty of Medicine and Health, Orebro University, 
      Orebro, Sweden.
LA  - eng
PT  - Journal Article
DEP - 20230824
PL  - Switzerland
TA  - Front Med (Lausanne)
JT  - Frontiers in medicine
JID - 101648047
PMC - PMC10484101
OTO - NOTNLM
OT  - body mass index
OT  - health-related quality of life
OT  - patient perspective
OT  - patient reported outcomes
OT  - systemic lupus erythematosus
COIS- IP has received research funding and honoraria from Amgen, AstraZeneca, Aurinia 
      Pharmaceuticals, Elli Lilly and Company, Gilead Sciences, GlaxoSmithKline, 
      Janssen Pharmaceuticals, Novartis and F. Hoffmann-La Roche AG. The remaining 
      authors declare that the research was conducted in the absence of any commercial 
      or financial relationships that could be construed as a potential conflict of 
      interest.
EDAT- 2023/09/11 06:43
MHDA- 2023/09/11 06:44
PMCR- 2023/08/24
CRDT- 2023/09/11 04:42
PHST- 2023/06/26 00:00 [received]
PHST- 2023/08/15 00:00 [accepted]
PHST- 2023/09/11 06:44 [medline]
PHST- 2023/09/11 06:43 [pubmed]
PHST- 2023/09/11 04:42 [entrez]
PHST- 2023/08/24 00:00 [pmc-release]
AID - 10.3389/fmed.2023.1247354 [doi]
PST - epublish
SO  - Front Med (Lausanne). 2023 Aug 24;10:1247354. doi: 10.3389/fmed.2023.1247354. 
      eCollection 2023.